Alzheimer's drug-development pipeline: 2016

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Volumn 2, Issue 4, 2016, Pages 222-232

  Cummings, Jeffrey ^a   Morstorf, Travis ^b   Lee, Garam ^a  

^a Lou Ruvo Center for Brain Health   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

Author keywords

Alzheimer's disease; Amyloid; Biomarkers; Cognitive enhancement; Drug development; Phase I; Phase II; Phase III; Tau

Indexed keywords

ADUCANUMAB; AMYLOID; ARGININE; ARIPIPRAZOLE; BETA SECRETASE; BIOLOGICAL MARKER; BREXPIPRAZOLE; CRENEZUMAB; ENCENICLINE; FLUORODEOXYGLUCOSE; FORMOTEROL; GANTENERUMAB; IDALOPIRDINE; INSULIN; LEVETIRACETAM; MASITINIB; NABILONE; NILVADIPINE; OXALOACETIC ACID; PIMAVANSERIN; PIOGLITAZONE; PIROMELATINE; RASAGILINE; RILUZOLE; SEMBRAGILINE; SOLANEZUMAB; TAU PROTEIN; TELMISARTAN; TETRAHYDROBIOPTERIN; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; COGNITION; DRUG DESIGN; DRUG MECHANISM; HUMAN; IMMUNOTHERAPY; NUCLEAR MAGNETIC RESONANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 84991735618     PISSN: None     EISSN: 23528737     Source Type: Journal    
DOI: 10.1016/j.trci.2016.07.001     Document Type: Article

References (21)

1. [1] Alzheimer's Association. 2015 Alzheimer's disease facts and figures. Alzheimers Dement 11 (2015), 332–384.
2. [2] Sosa-Ortiz, A.L., Acosta-Castillo, I., Prince, M.J., Epidemiology of dementias and Alzheimer's disease. Arch Med Res 43 (2012), 600–608.
3. [3] Cummings, J.L., Morstorf, T., Zhong, K., Alzheimer's disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res Ther, 6, 2014, 37.
4. [4] Tasneem, A., Aberle, L., Ananth, H., Chakraborty, S., Chiswell, K., McCourt, B.J., et al. The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty. PLoS One, 7, 2012, e33677.
5. [5] Berk, C., Paul, G., Sabbagh, M., Investigational drugs in Alzheimer's disease: current progress. Expert Opin Investig Drugs 23 (2014), 837–846.
6. [6] Cummings, J.L., Controversies in Alzheimer's disease drug development. Int Rev Psychiatry 20 (2008), 389–395.
7. [7] Wiendl, H., Elger, C., Forstl, H., Hartung, H.P., Oertel, W., Reichmann, H., et al. Gaps between aims and achievements in therapeutic modification of neuronal damage (“Neuroprotection”). Neurotherapeutics 12 (2015), 449–454.
8. [8] Appleby, B.S., Nacopoulos, D., Milano, N., Zhong, K., Cummings, J.L., A review: treatment of Alzheimer's disease discovered in repurposed agents. Dement Geriatr Cogn Disord 35 (2013), 1–22.
9. [9] Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., Kivipelto, M., Alzheimer's disease: clinical trials and drug development. Lancet Neurol 9 (2010), 702–716.
10. [10] Tufts Center for the Study of Drug Development. Clinical success rates for new cancer drugs double while more enter testing. Kenneth, I., Kaitin, P., (eds.) Impact Report, 2013, Tufts University, Boston, MA, 1–4.
11. [11] Mullard, A., 2015 FDA drug approvals. Nat Rev Drug Discov 15 (2016), 73–76.
12. [12] Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 311–321.
13. [13] Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 322–333.
14. [14] Sevigny, J., Suhy, J., Chiao, P., Chen, T., Klein, G., Purcell, D., et al. Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: Experience in a Phase 1b clinical trial. Alzheimer Dis Assoc Disord 30 (2016), 1–7.
15. [15] Menting, K.W., Claassen, J.A., Beta-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease. Front Aging Neurosci, 6, 2014, 165.
16. [16] Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13 (2014), 419–431.
17. [17] Brier, M.R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., et al. Tau and Abeta imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med, 8, 2016, 338ra66.
18. [18] Gordon, B.A., Friedrichsen, K., Brier, M., Blazey, T., Su, Y., Christensen, J., et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain 139 (2016), 2249–2260.
19. [19] Ossenkoppele, R., Schonhaut, D.R., Scholl, M., Lockhart, S.N., Ayakta, N., Baker, S.L., et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain 139 (2016), 1551–1567.
20. [20] Scholl, M., Lockhart, S.N., Schonhaut, D.R., O'Neil, J.P., Janabi, M., Ossenkoppele, R., et al. PET Imaging of tau deposition in the aging human brain. Neuron 89 (2016), 971–982.
21. [21] Perry, D., Sperling, R., Katz, R., Berry, D., Dilts, D., Hanna, D., et al. Building a roadmap for developing combination therapies for Alzheimer's disease. Expert Rev Neurother 15 (2015), 327–333.